12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eperzan albiglutide regulatory update

GlaxoSmithKline submitted an MAA to EMA for Eperzan albiglutide to treat Type II diabetes. The pharma submitted an NDA...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >